Difference between sensitivity and specificity
sensitivity specificity diagnostic test statistics
sensitivity specificity 2x2 contingency table diagnostic test
| Sensitivity | Specificity | |
|---|---|---|
| Also called | True Positive Rate | True Negative Rate |
| Question answered | "If the disease IS present, how often does the test correctly say YES?" | "If the disease is NOT present, how often does the test correctly say NO?" |
| Formula | TP / (TP + FN) | TN / (TN + FP) |
| Misses | False Negatives | False Positives |
Disease + Disease −
Test Positive | True Positive | False Positive |
Test Negative | False Negative | True Negative |

| Priority | Use High Sensitivity | Use High Specificity |
|---|---|---|
| Goal | Don't miss disease (rule out) | Confirm disease (rule in) |
| When false negatives are costly | Screening tests (e.g., HIV ELISA, cancer screening) | Confirmatory tests (e.g., HIV Western blot) |
| Consequence of error | Missing a treatable/dangerous disease | Unnecessary treatment or patient harm |
Post exposure prophylaxis for needle stick injury
post exposure prophylaxis needle stick injury HIV
needle stick injury PEP hepatitis B hepatitis C management
HIV PEP regimen antiretroviral drugs preferred regimen occupational exposure
hepatitis B post exposure prophylaxis HBIG vaccination needle stick occupational
Treat as a medical emergency — PEP must be started within 72 hours (ideally within 1–2 hours). Efficacy drops significantly with delay and is ineffective after 72 hours. (Harrison's, p. 5977)
| Factor | Increases Transmission Risk |
|---|---|
| Deep percutaneous injury | ✓ |
| Visible blood on device | ✓ |
| Device placed in source's vein/artery | ✓ |
| Advanced HIV disease / high viral load in source | ✓ |
| Hollow-bore needle vs. solid needle | ✓ (hollow > solid) |
| Regimen | Drugs |
|---|---|
| Preferred | Tenofovir/Emtricitabine (TDF/FTC) + Raltegravir OR Dolutegravir |
| Alternative | TDF/FTC + Lopinavir/ritonavir |
| Timepoint | Test |
|---|---|
| Baseline | HIV Ag/Ab (4th generation) |
| 6 weeks | HIV Ag/Ab |
| 3 months | HIV Ag/Ab |
| 6 months | HIV Ag/Ab (if source HCV+, extend to 6 months) |
| Exposed HCW Status | Source HBsAg+ | Source Unknown/Not Tested |
|---|---|---|
| Unvaccinated | HBIG × 1 + start HBV vaccine series | Start HBV vaccine series |
| Vaccinated, known responder (anti-HBs ≥10 mIU/mL) | No treatment needed | No treatment needed |
| Vaccinated, known non-responder | HBIG × 2 (1 month apart) OR HBIG × 1 + revaccinate | If high-risk source: treat as HBsAg+ |
| Vaccinated, unknown response | Test exposed person for anti-HBs; if inadequate → HBIG + booster | Test anti-HBs; if adequate → no Rx |
No effective PEP exists for Hepatitis C. (Harrison's, p. 9430)
| Pathogen | PEP Available? | Agent | Start Within | Duration |
|---|---|---|---|---|
| HIV | Yes | TDF/FTC + Dolutegravir (preferred) | 72 hours | 28 days |
| Hepatitis B | Yes (if unvaccinated/non-immune) | HBIG ± vaccine | 24–48 hours | Single dose HBIG |
| Hepatitis C | No | Monitor + treat if infected | N/A | Early DAA therapy |
Write answer for Question no. 2
Yes
Write answer of question 5